PetCaseFinder

Peer-reviewed veterinary case report

Vaccine protects beagle dogs from leptospirosis infection and symptoms

By Noel, Teola et al.·Published in Pathogens (Basel, Switzerland)·2025·School of Veterinary Medicine·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Vaccination-Challenge Trials in Beagle Dogs Using Whole-CellSerovar Copenhageni Vaccine: Prevention of Clinical Leptospirosis, Serological, Leptospiremia, Leptospiruria, Cytokines, Hematological, and Pathological Changes.

Species:
dog
Canine leptospirosisStomach & digestionDogs

Plain-English summary

A group of 12 beagle puppies received a new vaccine designed to protect against leptospirosis, a serious infection that can cause kidney and liver problems. After vaccination, the puppies were exposed to the bacteria, and none developed severe symptoms, while all unvaccinated puppies showed signs of the disease. The vaccinated dogs had a strong immune response and fewer signs of infection compared to the unvaccinated group. This study suggests that the vaccine is effective in preventing leptospirosis in dogs, but more research is needed to confirm these results with a larger number of dogs.

People also search for: beagle leptospirosis vaccine · symptoms of leptospirosis in dogs · how to prevent leptospirosis in dogs

Abstract

A killed, whole-cell vaccine was produced to induce immunity in dogs against leptospirosis. The vaccine, containing serovar Copenhageni, was produced and administered to 12 beagle dogs at both 8 and 12 weeks of age. Ten unvaccinated dogs of the same age group served as the control group. A live, virulent inoculum of(1.52 × 10-4.40 × 10leptospires per dog) was used to challenge the dogs at 2 weeks (Study 1) and 14 months (Study 2) post-booster vaccination. At regular intervals, pre- and post-challenge (PC), the microscopic agglutination test (MAT) was performed to measure antibody titers. Leptospiremia and leptospiruria were determined via culture, and the cytokine, biochemical, and pathological profiles of vaccinates and controls were also assessed. A high antibody response was measurable after booster administration. In Study 1 (onset of immunity), acute leptospirosis was observed in five (100%) out of five unvaccinated dogs. In contrast, no acute clinical leptospirosis developed in vaccinated dogs, except in one (20%) dog with mild clinical signs. In Study 2 (duration of immunity), mild clinical signs were observed in two (40%) of the control dogs, while all vaccinated dogs remained clinically normal. The incidence of leptospiruria and leptospiremia PC was lower in the vaccinated dogs compared to the unvaccinated group. Severe thrombocytopenia occurred in 100% (5/5) of the unvaccinated dogs in Study 1 that exhibited acute severe leptospirosis, whereas 80% (4/5) of the unvaccinated dogs in Study 2 showed mild to moderate thrombocytopenia 3 days after challenge. Four out of five unvaccinated dogs (80%) in Study 1 exhibited icteric tissues and hemorrhages in the lungs and mucosal surfaces of the stomach and intestines. A high IL-10 to TNF-α ratio, observed in the control group of both studies, and severe thrombocytopenia observed in the control group of Study 1, indicative of acute leptospiral disease, were detected. The vaccine prevented acute clinical leptospirosis and reduced the renal carrier state in beagle dogs, and further investigation is required using a larger sample size.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40732660/